Host cytokine genetic polymorphisms in a selected population of persons living with hepatitis B virus infection in the central region of Ghana.
Humans
Ghana
Female
Male
Adult
Cross-Sectional Studies
Cytokines
/ genetics
Middle Aged
Hepatitis B virus
/ genetics
Tumor Necrosis Factor-alpha
/ genetics
Hepatitis B
/ genetics
Interleukin-18
/ genetics
Interferon-gamma
/ genetics
Interleukin-10
/ genetics
Interleukin-6
/ genetics
Genotype
Young Adult
Hepatitis B, Chronic
/ genetics
Polymorphism, Single Nucleotide
Polymorphism, Genetic
Interleukins
/ genetics
Interleukin-4
Interleukin-8
Cytokines
Genetics
HBV
Hepatitis
IFN-γ
IL-10
IL-18
IL-2
TNF-α
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
22 Oct 2024
22 Oct 2024
Historique:
received:
01
05
2024
accepted:
09
10
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
21
10
2024
Statut:
epublish
Résumé
Hepatitis B virus (HBV) infection is a public health concern in resource limited settings like Ghana. Over the past decades, it is noted that the natural course of HBV in persons infected are taking a worse turn leading to liver cirrhosis and cancer. The outcome of HBV infection is influenced by viral and host factors including genetics. Cytokine variations affect virus survival and progression and may even influence associated complications. Cytokines such as tumor necrosis factor alpha (TNF-α), interleukins (IL-4, IL-6, IL-8, IL-10, IL-18), interferon gamma (IFN)-γ, and tumor growth factor-beta (TGF-β) have key roles in HBV infection and modulation. In this study, polymorphisms occurring in five cytokines were analysed to understand how they can influence prognosis of HBV infection. The study is a single centre cross-sectional study involving 227 participants made up of HBV infected participants and HBV-negative controls. Recruitment was from March 2021 to April 2022. Blood samples were taken for full blood count, HBV antigen profile, liver function tests, HBV DNA quantification and cytokine genotyping. FIB score was calculated using available tools. Statistical analysis was undertaken with p < 0.05 set as statistically significant. The 20-39-year-old group formed majority of the HBV infected participants with 60% of all participants being classified as healthy HBsAg carriers. IL2 rs1479920 GG carriers ((1258.93; 0.00-5011.87) IU/mL had reduced HBV DNA in comparison to IL2 rs1479920 AA ((5011.87; 2113.49-5956.62) /AG (3548.13; 0.00-6309.57) IU/mL carriers. TNF-α rs1800629 AA carriers (1258.93; 0.00-3981.07) IU/mL had a reduction in HBV DNA levels in comparison to TNF-α rs1800629 GG carriers (1584.89; 0.00-5011.87) IU/mL. The results of univariate (OR = 0.08, 0.00-0.93; p = 0.043) and multivariate (OR = 0.02, 0.00-0.67; p = 0.029) analysis, showed that carrying TNF-α rs1800629 AA genotype reduce susceptibility to high FIB score compared with GG genotypes. In univariate analysis, subjects aged 20-39 years (OR = 5.00, 1.13-6.10; p = 0.034) and 40-59 years (OR = 41.99, 3.74-47.21; p = 0.0002) were more susceptible to high FIB score compared to subjects aged 1-19 years. Being female (OR = 2.42, 1.03-5.71; p = 0.043) in the univariate models showed higher odds of having high levels of HBV DNA in the multivariate model. There was a reduced likelihood of herbal medicine usage influencing HBV DNA levels significantly (OR = 0.29, 0.10-0.86; p = 0.025). In conclusion, variations in IL2 rs1479920 GG and IL2 rs1479921 AA could offer protective effects by reducing HBV DNA. TNF-α rs179924CT may also cause elevation in HBV DNA levels whiles TNF-α -308A/G, showed a potential protective effect on liver scarring in HBV infected participants. It is therefore important to take a further look at such variations for understanding of HBV modulation in the Ghanaian population.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis B virus (HBV) infection is a public health concern in resource limited settings like Ghana. Over the past decades, it is noted that the natural course of HBV in persons infected are taking a worse turn leading to liver cirrhosis and cancer. The outcome of HBV infection is influenced by viral and host factors including genetics. Cytokine variations affect virus survival and progression and may even influence associated complications. Cytokines such as tumor necrosis factor alpha (TNF-α), interleukins (IL-4, IL-6, IL-8, IL-10, IL-18), interferon gamma (IFN)-γ, and tumor growth factor-beta (TGF-β) have key roles in HBV infection and modulation. In this study, polymorphisms occurring in five cytokines were analysed to understand how they can influence prognosis of HBV infection.
METHODS
METHODS
The study is a single centre cross-sectional study involving 227 participants made up of HBV infected participants and HBV-negative controls. Recruitment was from March 2021 to April 2022. Blood samples were taken for full blood count, HBV antigen profile, liver function tests, HBV DNA quantification and cytokine genotyping. FIB score was calculated using available tools. Statistical analysis was undertaken with p < 0.05 set as statistically significant.
RESULTS
RESULTS
The 20-39-year-old group formed majority of the HBV infected participants with 60% of all participants being classified as healthy HBsAg carriers. IL2 rs1479920 GG carriers ((1258.93; 0.00-5011.87) IU/mL had reduced HBV DNA in comparison to IL2 rs1479920 AA ((5011.87; 2113.49-5956.62) /AG (3548.13; 0.00-6309.57) IU/mL carriers. TNF-α rs1800629 AA carriers (1258.93; 0.00-3981.07) IU/mL had a reduction in HBV DNA levels in comparison to TNF-α rs1800629 GG carriers (1584.89; 0.00-5011.87) IU/mL. The results of univariate (OR = 0.08, 0.00-0.93; p = 0.043) and multivariate (OR = 0.02, 0.00-0.67; p = 0.029) analysis, showed that carrying TNF-α rs1800629 AA genotype reduce susceptibility to high FIB score compared with GG genotypes. In univariate analysis, subjects aged 20-39 years (OR = 5.00, 1.13-6.10; p = 0.034) and 40-59 years (OR = 41.99, 3.74-47.21; p = 0.0002) were more susceptible to high FIB score compared to subjects aged 1-19 years. Being female (OR = 2.42, 1.03-5.71; p = 0.043) in the univariate models showed higher odds of having high levels of HBV DNA in the multivariate model. There was a reduced likelihood of herbal medicine usage influencing HBV DNA levels significantly (OR = 0.29, 0.10-0.86; p = 0.025).
CONCLUSION
CONCLUSIONS
In conclusion, variations in IL2 rs1479920 GG and IL2 rs1479921 AA could offer protective effects by reducing HBV DNA. TNF-α rs179924CT may also cause elevation in HBV DNA levels whiles TNF-α -308A/G, showed a potential protective effect on liver scarring in HBV infected participants. It is therefore important to take a further look at such variations for understanding of HBV modulation in the Ghanaian population.
Identifiants
pubmed: 39434005
doi: 10.1186/s12876-024-03456-9
pii: 10.1186/s12876-024-03456-9
doi:
Substances chimiques
Cytokines
0
Tumor Necrosis Factor-alpha
0
Interleukin-18
0
Interferon-gamma
82115-62-6
Interleukin-10
130068-27-8
IL18 protein, human
0
Interleukin-6
0
IL10 protein, human
0
IL6 protein, human
0
IL4 protein, human
0
CXCL8 protein, human
0
Interleukins
0
Interleukin-4
207137-56-2
Interleukin-8
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
374Informations de copyright
© 2024. The Author(s).
Références
Collaborators PO. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023;8(10):879–907.
doi: 10.1016/S2468-1253(23)00197-8
World Health Organization. Regional Office for A. 91 million Africans infected with Hepatitis B or C 2022. Available from: https://www.afro.who.int/news/91-million-africans-infected-hepatitis-b-or-c .
Patmore LA, van Eekhout KMA, Buti M, Koc ÖM, Agarwal K, de Knegt RJ, et al. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe. J Hepatol. 2024;80(2):243–50.
pubmed: 37898348
doi: 10.1016/j.jhep.2023.10.019
Ndububa DA. Liver cancer surveillance in people with hepatitis B in Africa. The Lancet Gastroenterology & Hepatology. 2024.
Ofori-Asenso R, Agyeman AA. Hepatitis B in Ghana: a systematic review and meta-analysis of prevalence studies (1995–2015). BMC Infect Dis. 2016;16:130.
pubmed: 26987556
pmcid: 4797341
doi: 10.1186/s12879-016-1467-5
Abesig J, Chen Y, Wang H, Sompo FM, Wu IXY. Prevalence of viral hepatitis B in Ghana between 2015 and 2019: a systematic review and meta-analysis. PLoS ONE. 2020;15(6):e0234348.
pubmed: 32530945
pmcid: 7292378
doi: 10.1371/journal.pone.0234348
Adanusa M, Adjei G, Eliason S, Amoah S, Benson C, Sirikyi I, et al. Sero-prevalence of Hepatitis B and C at a Primary Healthcare centres in Ghana AfricArXiv. 2023.
Luuse A, Dassah S, Lokpo S, Ameke L, Noagbe M, Adatara P, et al. Sero-Prevalence of Hepatitis B Surface Antigen Amongst Pregnant Women Attending an Antenatal Clinic, Volta Region, Ghana. J Public Health Afr. 2016;7(2):584.
pubmed: 28299162
Nartey YA, Antwi SO, Bockarie AS, Hiebert L, Njuguna H, Ward JW, et al. Mortality burden due to liver cirrhosis and hepatocellular carcinoma in Ghana; prevalence of risk factors and predictors of poor in-hospital survival. PLoS ONE. 2022;17(9):e0274544.
pubmed: 36099308
pmcid: 9469955
doi: 10.1371/journal.pone.0274544
Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479–480:672–86.
pubmed: 25759099
doi: 10.1016/j.virol.2015.02.031
Wang J, Wu X, Kuniya T. Analysis of a diffusive HBV model with logistic proliferation and non-cytopathic antiviral mechanisms. Commun Nonlinear Sci Numer Simul. 2022;106:106110.
doi: 10.1016/j.cnsns.2021.106110
Zai W, Hu K, Ye J, Ding J, Huang C, Li Y, et al. Long-Term Hepatitis B Virus Infection Induces Cytopathic Effects in Primary Human Hepatocytes, and Can Be Partially Reversed by Antiviral Therapy. Microbiology Spectrum. 2022;10(1):e01328–e1421.
pubmed: 35171034
pmcid: 8849052
doi: 10.1128/spectrum.01328-21
Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discovery. 2018;17(1):35–56.
pubmed: 28935918
doi: 10.1038/nrd.2017.162
Busca A, Kumar A. Innate immune responses in hepatitis B virus (HBV) infection. Virology Journal. 2014;11(1):22.
pubmed: 24507433
pmcid: 3922976
doi: 10.1186/1743-422X-11-22
Cui D, Jiang D, Yan C, Liu X, Lv Y, Xie J, et al. Immune checkpoint molecules expressed on CD4+ T cell subsets in chronic asymptomatic hepatitis B virus carriers with hepatitis B e antigen-negative. Front Microbiol. 2022;13:887408.
pubmed: 35572697
pmcid: 9093708
doi: 10.3389/fmicb.2022.887408
Zheng P, Dou Y, Wang Q. Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity. Front Cellular Infect Microbiol. 2023;13:1206720.
doi: 10.3389/fcimb.2023.1206720
Chuang Y-C, Tsai K-N, Ou J-HJ. Pathogenicity and virulence of Hepatitis B virus. Virulence. 2022;13(1):258–96.
pubmed: 35100095
pmcid: 8812780
doi: 10.1080/21505594.2022.2028483
Shin E-C, Sung PS, Park S-H. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16(8):509–23.
pubmed: 27374637
doi: 10.1038/nri.2016.69
Chang M-L, Liaw Y-F. Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management. J Hepatol. 2014;61(6):1407–17.
pubmed: 25178562
doi: 10.1016/j.jhep.2014.08.033
Ferreira SC, Chachá SG, Souza FF, Teixeira AC, Santana RC, Villanova MG, et al. Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. Ann Hepatol. 2014;13(6):762–70.
pubmed: 25332262
doi: 10.1016/S1665-2681(19)30978-0
Tunçbilek S. Relationship between cytokine gene polymorphisms and chronic hepatitis B virus infection. World J Gastroenterol. 2014;20(20):6226–35.
pubmed: 24876743
pmcid: 4033460
doi: 10.3748/wjg.v20.i20.6226
Xu J, Zhan Q, Fan Y, Yu Y, Zeng Z. Human genetic susceptibility to hepatitis B virus infection. Infect Genet Evol. 2021;87:104663.
pubmed: 33278635
doi: 10.1016/j.meegid.2020.104663
Ribeiro CRdA, de Almeida NAA, Martinelli KG, Pires MA, Mello CEB, Barros JJ, et al. Cytokine profile during occult hepatitis B virus infection in chronic hepatitis C patients Virol J. 2021;18(1):15.
pubmed: 33435966
Zhong S, Zhang T, Tang L, Li Y. Cytokines and Chemokines in HBV Infection. Frontiers in Molecular Biosciences. 2021;8:805625.
pubmed: 34926586
pmcid: 8674621
doi: 10.3389/fmolb.2021.805625
Dimitriadis K, Katelani S, Pappa M, Fragkoulis GE, Androutsakos T. The Role of Interleukins in HBV Infection: A Narrative Review. Journal of Personalized Medicine. 2023;13(12):1675.
pubmed: 38138902
pmcid: 10744424
doi: 10.3390/jpm13121675
Buschow SI, Jansen DTSL. CD4+ T Cells in Chronic Hepatitis B and T Cell-Directed Immunotherapy. Cells. 2021;10(5):1114.
pubmed: 34066322
pmcid: 8148211
doi: 10.3390/cells10051114
Heim K, Neumann-Haefelin C, Thimme R, Hofmann M. Heterogeneity of HBV-Specific CD8+ T-Cell failure: implications for immunotherapy. Front Immunol. 2019;10:2240.
pubmed: 31620140
pmcid: 6763562
doi: 10.3389/fimmu.2019.02240
Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol. 2003;98(1):144–50.
pubmed: 12526950
doi: 10.1111/j.1572-0241.2003.07179.x
Guo Z, Wu Q, Xie P, Wang J, Lv W. Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications. Front Immunol. 2024;15:1336493.
pubmed: 38352880
pmcid: 10861763
doi: 10.3389/fimmu.2024.1336493
Nati M, Chung K-J, Chavakis T. The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease. J Innate Immun. 2021;14(1):31–41.
pubmed: 34515137
pmcid: 8787511
doi: 10.1159/000518407
Bourdon M, Manet C, Montagutelli X. Host genetic susceptibility to viral infections: the role of type I interferon induction. Genes Immun. 2020;21(6–8):365–79.
pubmed: 33219336
pmcid: 7677911
doi: 10.1038/s41435-020-00116-2
Frodsham AJ. Host genetics and the outcome of hepatitis B viral infection. Transpl Immunol. 2005;14(3):183–6.
pubmed: 15982561
doi: 10.1016/j.trim.2005.03.006
Wungu CDK, Ariyanto FC, Prabowo GI, Soetjipto S, Handajani R. Meta-analysis: Association between hepatitis B virus preS mutation and hepatocellular carcinoma risk. J Viral Hepatitis. 2021;28(1):61–71.
doi: 10.1111/jvh.13402
Rybicka M, Woziwodzka A, Romanowski T, Sznarkowska A, Stalke P, Dręczewski M, et al. Host genetic background affects the course of infection and treatment response in patients with chronic hepatitis B. J Clin Virol. 2019;120:1–5.
pubmed: 31505315
doi: 10.1016/j.jcv.2019.09.002
Ortonne V, Wlassow M, Bouvier-Alias M, Melica G, Poveda JD, Laperche S, et al. Diagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas(®) HBV Test for Use on the Cobas(®) 4800 System. Microorganisms. 2021;9(3):573.
pubmed: 33799562
pmcid: 7999133
doi: 10.3390/microorganisms9030573
Allice T, Cerutti F, Pittaluga F, Varetto S, Gabella S, Marzano A, et al. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. J Clin Microbiol. 2007;45(3):828–34.
pubmed: 17229858
pmcid: 1829141
doi: 10.1128/JCM.00914-06
Chevaliez S, Bouvier-Alias M, Laperche S, Hézode C, Pawlotsky JM. Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol. 2010;48(10):3641–7.
pubmed: 20720031
pmcid: 2953086
doi: 10.1128/JCM.01306-10
Kim BK, Kim DY, Park JY, Ahn SH, Chon CY, Kim JK, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010;30(4):546–53.
pubmed: 20074094
doi: 10.1111/j.1478-3231.2009.02192.x
Millis MP. Medium-throughput SNP genotyping using mass spectrometry: multiplex SNP genotyping using the iPLEX® Gold assay. Methods Mol Biol. 2011;700:61–76.
pubmed: 21204027
doi: 10.1007/978-1-61737-954-3_5
Lakshminarasimhappa MC. Web-Based and Smart Mobile App for Data Collection: Kobo Toolbox / Kobo Collect. 2022. 2022;57(2):8.
Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31(21):3555–7.
pubmed: 26139635
pmcid: 4626747
doi: 10.1093/bioinformatics/btv402
Shen J, Li Z, Chen J, Song Z, Zhou Z, Shi Y. SHEsisPlus, a toolset for genetic studies on polyploid species. Sci Rep. 2016;6:24095.
pubmed: 27048905
pmcid: 4822172
doi: 10.1038/srep24095
Gusatti CdS, Costi C, de Medeiros RM, Halon ML, Grandi T, Medeiros AFR, et al. Association between cytokine gene polymorphisms and outcome of hepatitis B virus infection in southern Brazil. J Med Virol. 2016;88(10):1759–66.
pubmed: 26959287
doi: 10.1002/jmv.24518
Fabricio-Silva GM, Poschetzky BS, de Mello PR, Dos Santos RC, Cavalini LT, Porto LC. Association of cytokine gene polymorphisms with hepatitis C virus infection in a population from Rio de Janeiro. Brazil Hepat Med. 2015;7:71–9.
pubmed: 26586969
Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y, et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int. 2011;31(8):1118–26.
pubmed: 21745278
doi: 10.1111/j.1478-3231.2011.02507.x
Karimi MH, Yaghobi R, Arjmandi K, Geramizadeh B, Nikeghbalian S, Malekhosseini SA. Cytokine Gene Polymorphisms and Viral Hepatitis Infections in Kidney Transplant Recipients. Laboratory Medicine. 2013;44(2):114–20.
doi: 10.1309/LMSHLD2N8MOLBO1N
Pol JG, Caudana P, Paillet J, Piaggio E, Kroemer G. Effects of interleukin-2 in immunostimulation and immunosuppression. J Exp Med. 2019;217(1):e20191247.
pmcid: 7037245
doi: 10.1084/jem.20191247
Bendickova K, Fric J. Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy. J Leukoc Biol. 2020;108(1):427–37.
pubmed: 32480431
doi: 10.1002/JLB.5MIR0420-055R
Horie Y, Chiba M, Suzuki T, Kudo T, Kamata A, Iizuka M, et al. Induction of major histocompatibility complex class II antigens on human colonic epithelium by interferon-gamma, tumor necrosis factor-alpha, and interleukin-2. J Gastroenterol. 1998;33(1):39–47.
pubmed: 9497220
Wei Y, Zhao Z, Wang Z, Zhang K, Tang Z, Tao C. Relationships between IL-1β, TNF-α genetic polymorphisms and HBV infection: A meta-analytical study. Gene. 2021;791:145617.
pubmed: 33775848
doi: 10.1016/j.gene.2021.145617
Li Y, Zhou H, Wu W, Zhang W, Ye Y, Jia W, et al. Associations between single nucleotide polymorphisms of cytokines and hepatitis B virus-related liver cirrhosis: A case-control study. Immun Inflamm Dis. 2024;12(9):e70017.
pubmed: 39315805
pmcid: 11421045
doi: 10.1002/iid3.70017
Wungu CDK, Ariyanto FC, Prabowo GI, Soetjipto, Handajani R. Association between five types of Tumor Necrosis Factor-α gene polymorphism and hepatocellular carcinoma risk: a meta-analysis. BMC Cancer. 2020;20(1):1134.
pubmed: 33228594
pmcid: 7686711
doi: 10.1186/s12885-020-07606-6
Zhu QR, Ge YL, Gu SQ, Yu H, Wang JS, Gu XH, et al. Relationship between cytokines gene polymorphism and susceptibility to hepatitis B virus intrauterine infection. Chin Med J (Engl). 2005;118(19):1604–9.
pubmed: 16232344
Basturk B, Karasu Z, Kilic M, Ulukaya S, Boyacioglu S, Oral B. Association of TNF-alpha -308 polymorphism with the outcome of hepatitis B virus infection in Turkey. Infect Genet Evol. 2008;8(1):20–5.
pubmed: 17974504
doi: 10.1016/j.meegid.2007.09.001
Heidari Z, Moudi B, Mahmoudzadeh Sagheb H, Moudi M. Association of TNF-α Gene Polymorphisms with Production of Protein and Susceptibility to Chronic Hepatitis B Infection in the South East Iranian Population. Hepat Mon. 2016;16(11):e41984.
pubmed: 28070201
pmcid: 5203729
doi: 10.5812/hepatmon.41984
Wu JF, Ni YH, Lin YT, Lee TJ, Hsu SH, Chen HL, et al. Human interleukin-10 genotypes are associated with different precore/core gene mutation patterns in children with chronic hepatitis B virus infection. J Pediatr. 2011;158(5):808–13.
pubmed: 21168854
doi: 10.1016/j.jpeds.2010.11.015
Gao L, Chen X, Zhang L, Wu D, Zhao H, Niu J. Association of IL-10 polymorphisms with hepatitis B virus infection and outcome in Han population. Eur J Med Res. 2016;21(1):23.
pubmed: 27245049
pmcid: 4888478
doi: 10.1186/s40001-016-0218-9
Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H, Hashemi M, Metanat M, Khosravi S, et al. Association Between IL-10 Gene Promoter Polymorphisms (-592 A/C, -819 T/C, -1082 A/G) and Susceptibility to HBV Infection in an Iranian Population. Hepat Mon. 2016;16(2):e32427.
pubmed: 27148384
pmcid: 4852092
doi: 10.5812/hepatmon.32427
Terrando N, Monaco C, Ma D, Foxwell BMJ, Feldmann M, Maze M. Tumor necrosis factor-α triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci. 2010;107(47):20518–22.
pubmed: 21041647
pmcid: 2996666
doi: 10.1073/pnas.1014557107
Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: From Clinical Significance to Quantification. Advanced Science. 2021;8(15):2004433.
pubmed: 34114369
pmcid: 8336501
doi: 10.1002/advs.202004433
Jeng JE, Tsai JF, Chuang LY, Ho MS, Lin ZY, Hsieh MY, et al. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia. 2007;9(11):987–92.
pubmed: 18030367
doi: 10.1593/neo.07781
Elbrolosy AM, Elabd NS, ElGedawy GA, Abozeid M, Abdelkreem M, Montaser B, et al. Toll- like receptor 2 polymorphism and IL-6 profile in relation to disease progression in chronic HBV infection: a case control study in Egyptian patients. Clin Exp Med. 2023;23(1):117–29.
pubmed: 35119591
Temel EN, Akcam FZ, Caner V, Bagci G, Tepebasi MY. Relationship between IL-17, TNF-alpha, IL-10, IFN-gamma, and IL-18 polymorphisms with the outcome of hepatitis B virus infection in the Turkish population. Rev Assoc Med Bras (1992). 2023;69(8):e20230355.
pubmed: 37585994
pmcid: 10427177
doi: 10.1590/1806-9282.20230355